ANTI-AGEING 35 Baseline
Panelist C1036 1. Forehead Lines
Baseline 4 weeks 12 weeks 4 weeks 8 weeks 12 weeks
Panelist LL888
1. Crow’s Feet Under Eye Lines
2. Nasolabial Folds
Figure 2: Clinical study using a finished formulation infused with the miR-29a-3p antagomiR. Shown are high resolution images of two panelists from a clinical study where the miR-29a-3p antagomiR was formulated into a cream and applied to the face twice-daily with measurements collected at baseline, four, eight and 12 weeks. Panelist CO136 had significant improvement to forehead lines with visible improvement at the four-week timepoint. Improvement was continuous and progressive. Panelist LL888 also saw significant improvement to crow’s feet, under eye lines, and nasolabial folds in the first four weeks of the study. In addition, both panelists had visible improvements to smoothness, texture, and firmness.
comprehensive combination of evaluation methods and instruments. Expert clinical grading was performed using a modified Griffiths ten-point scale to assess visible changes in skin condition. Non-invasive biophysical measurements, including ElastiMeter, Ultrasound, and Cutometer, were utilized to quantify improvements in skin elasticity, density and firmness. This comprehensive study demonstrated
that the miR-29a-3p antagomiR treated group experienced statistically significant results across virtually all measured parameters including: skin density, texture, smoothness, firmness, elasticity, and visible line reduction (Figure 2). In contrast, the placebo group showed no significant improvements across any of the measured parameters. This reinforces the improvements seen in the treated group.
TABLE 2 Gene
ACTA2 BGN
FBLN5 KL
VIM Key Function ECM remodeling Collagen organization
COL5A1 Collagen fibrillogenesis DCN
Collagen binding Elastic fibre formation
Modulates oxidative stress, longevity factor Fibroblast structure and migration
Conclusion As evidenced from the exceptional results obtained from the in vitro, ex vivo, and in vivo testing, the novel approach of delivering of RNA- based messages to skin cells produces highly beneficial outcomes – critical fibre protein levels are bolstered with youthful facial features being restored. Distilled down to its basics, the new paradigm
puts faith in the capacity of skin cells to be more effective at taking care of themselves with a little coaxing from an RNA-based ‘text message’. The strategy of ‘trusting our cells’ truly delivers on the long-standing hope of countering the negative impacts of biological ageing.
p. 169124
2. Good DJ. Non-Coding RNAs in Human Health and Diseases. Genes (Basel). 2023; 14(7)
3. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4): p. 642-55
4. Hajialiasgary Najafabadi A, Soheilifar MH, Masoudi-Khoram N. Exosomes in skin photoaging: biological functions and therapeutic opportunity. Cell Commun Signal. 2024; 22(1): p.32
PCM
References 1. Fine JL, Moses AM. An RNA Condensate Model for the Origin of Life. J Mol Biol. 2025; 437(12):
Skin Benefits
Maintains firmness and tone Maintains dermal density
Preserves firmness and structure Improves texture and elasticity Restores elasticity, reduces sagging
‘Youth gene’ - protects against inflammageing Supports ECM renewal and repair
Table 2: Gene expression changes detected in the ex vivo study with miR-29a-3p antagomiR topically applied to human skin explants. Human skin explants were topically treated with a formulation containing antagomiRs to miR-29a-3p and allowed to incubate for five days. Afterwards, the tissue was collected and the RNAs contained therein were purified. The RNA was then subject to RT-qPCR analysis against a panel of skin-relevant miRNA species. The expression data was plotted on a graph as shown relative to control specimens. ACTA2: alpha-2 actin. BGN: biglycan. COL5A1: type V collagen. DCN: decorin. FBLN5: fibulin-5. KL: klotho. VIM: vimentin
www.personalcaremagazine.com
5. Gallant-Behm CL et al. A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol. 2019; 139(5): p.1073-1081
6. Li D et al. MicroRNA-132 enhances transition from inflammation to proliferation during wound healing. J Clin Invest. 2015; 125(8): p. 3008-26
7. Rebane A et al. MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol. 2014; 134(4): p. 836-847 e11
8. Wang J et al. MicroRNA-205 promotes hair regeneration by modulating mechanical properties of hair follicle stem cells. Proc Natl Acad Sci USA. 2023; 120(22): p. e2220635120
9. Rambow F et al. miR-330-5p targets tyrosinase and induces depigmentation. J Invest Dermatol. 2014; 134(11): p. 2846-2849
10. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010; 70(18): p. 7027-30
11. Krutzfeldt J et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005; 438(7068): p. 685-9
January 2026 PERSONAL CARE MAGAZINE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
